Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “CTOR”

756 pharma patents match "CTOR" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 756
Index total 30,257
Page 18 / 32

Quick answer

This filtered view shows 756 pharmaceutical patents matching "CTOR" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

756 results for “CTOR” · 30,257 patents in full index Clear search

  1. US 9056907

    Human domain antibodies against components of the human insulin-like growth factor (IGF) system

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 16, 2015 · Expires Jun 11, 2035

    granted

  2. US 9050299

    Administration of growth factors for the treatment of CNS disorders

    The Regents of the University of California · Granted Jun 9, 2015 · Expires Jun 4, 2035

    granted

  3. US 9044483

    Cell death inhibition by macrophage migration inhibitory factor and a binding substance thereto

    Takeda Pharmaceutical Company Limited · Granted Jun 2, 2015 · Expires May 28, 2035

    granted

  4. US 9029502

    Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted May 12, 2015 · Expires May 7, 2035

    granted

  5. US 9023798

    Cystinosin replacement factor

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted May 5, 2015 · Expires Apr 30, 2035

    granted

  6. US 8993519

    Method of treatment for neutropenia using stable formulations of recombinant human albumin-human granulocyte colony stimulating factor

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Mar 31, 2015 · Expires Mar 26, 2035

    granted

  7. US 8987227

    Hepatitis C dsRNA effector molecules, expression constructs, compositions, and methods of use

    Alnylam Pharmaceuticals, Inc. · Granted Mar 24, 2015 · Expires Mar 19, 2035

    granted

  8. US 8962817

    Vectors encoding a paralytic peptide

    Soricimed Biopharma Inc. · Granted Feb 24, 2015 · Expires Feb 19, 2035

    granted

  9. US 8926987

    Replication-competent adenoviral vectors

    The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services · Granted Jan 6, 2015 · Expires Jan 1, 2035

    granted

  10. US 8911729

    Stem cell factor inhibitor

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Dec 16, 2014 · Expires Dec 11, 2034

    granted

  11. US 8906863

    Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector

    The Regents of the University of California · Granted Dec 9, 2014 · Expires Dec 4, 2034

    granted

  12. US 2014357564

    Von Willebrand Factor Variants Having Improved Factor VIII Binding Affinity

    CSL BEHRING GMBH [DE] · Granted Dec 4, 2014 · Expires Nov 29, 2034

    granted

  13. US 8901093

    Custom vectors for treating and preventing pancreatic cancer

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Dec 2, 2014 · Expires Nov 27, 2034

    granted

  14. US 8901141

    Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them

    Takeda Pharmaceutical Company Limited · Granted Dec 2, 2014 · Expires Nov 27, 2034

    granted

  15. US 8889625

    Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia

    Northwestern University · Granted Nov 18, 2014 · Expires Nov 13, 2034

    granted

  16. US 8889831

    Unit dosage forms of pharmaceutical compositions comprising a polymer-factor VIII polypeptide conjugate

    Nektar Therapeutics · Granted Nov 18, 2014 · Expires Nov 13, 2034

    granted

  17. US 2014335071

    Composition Exhibiting a von Willebrand Factor (vWF) Protease Activity Comprising a Polypeptide Chain with the Amino Acid Sequence AAGGILHLELLV

    BAXTER INNOVATIONS GMBH [AT] · Granted Nov 13, 2014 · Expires Nov 8, 2034

    granted

  18. US 8865461

    Rabies virus vector systems and compositions and methods thereof

    The United States of America as represtented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention · Granted Oct 21, 2014 · Expires Oct 16, 2034

    granted

  19. US 8865748

    Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer

    Akebia Therapeutics, Inc. · Granted Oct 21, 2014 · Expires Oct 16, 2034

    granted

  20. US 8852936

    Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery

    Laurantis Pharma Oy · Granted Oct 7, 2014 · Expires Oct 2, 2034

    granted

  21. US 8846389

    AAV4 vector and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 30, 2014 · Expires Sep 25, 2034

    granted

  22. US 8822196

    Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 2, 2014 · Expires Aug 28, 2034

    granted

  23. US 8808684

    Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus type 6 (AAV6) transduction

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 19, 2014 · Expires Aug 14, 2034

    granted

  24. US 8778633

    Transcription factor modulator

    Molecular Discover Systems · Granted Jul 15, 2014 · Expires Jul 10, 2034

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.